patritumab
mAbexperimental
Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator. — Wikipedia
Clinical trial activity
24 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
18
Phase 3
3
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00730470)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 3
- Carcinoma · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Epidermal Growth Factor · Phase 3
- Gastrointestinal Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 2
- Hemangiosarcoma · Phase 2
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 1
- Mutation · Phase 2
- Neoplasm Metastasis · Early Phase 1
- Neoplasms · Phase 2
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- Receptor tyrosine-protein kinase erbB-3BINDING AGENT
Receptor tyrosine-protein kinase erbB-3 binding agent
ERBB3 inhibitor
- DNA topoisomerase IINHIBITOR
DNA topoisomerase I inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPatritumab ↗
- ChEMBLCHEMBL4594611 ↗
- ChEMBLCHEMBL2109406 ↗
- ChEMBLCHEMBL2109396 ↗
Also known as
- amg 888
- amg-888
- patritumab
- patritumab
- patritumab
- patritumab
- tracer
- u3-1287
- u3-1287
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07286149 | Phase 1/Phase 2 (Phase 2) | Feb 9, 2026 | Daiichi Sankyo, Merck |
| NCT07060807 | Phase 3 | Jul 21, 2025 | Daiichi Sankyo, Merck |
| NCT06941272 | Phase 1/Phase 2 (Phase 2) | May 26, 2025 | Daiichi Sankyo, Merck |
| NCT06797635 | Phase 2 | Mar 3, 2025 | Daiichi Sankyo, Merck |
| NCT06686394 | Phase 1/Phase 2 (Phase 2) | Dec 19, 2024 | Daiichi Sankyo, Merck |
| NCT06596694 | Phase 1/Phase 2 (Phase 2) | Oct 30, 2024 | Daiichi Sankyo, Merck |
| NCT06383884 | Phase 2 | May 30, 2024 | Sungkyunkwan University |
| NCT06222489 | Phase 2 | May 1, 2024 | Daiichi Sankyo, Netherlands Cancer Institute |
| NCT06298084 | Phase 1/Phase 2 (Phase 2) | Mar 21, 2024 | Daiichi Sankyo, Institut Gustave Roussy |
| NCT05865990 | Phase 2 | Sep 30, 2023 | Daiichi Sankyo, Medical University of Vienna, MedSIR |
| NCT05620914 | Early Phase 1 (Phase 1) | Dec 31, 2022 | Daiichi Sankyo, Duke University |
| NCT05569811 | Phase 2 | Nov 25, 2022 | Daiichi Sankyo, SOLTI Breast Cancer Research Group |
| NCT05338970 | Phase 3 | May 10, 2022 | Daiichi Sankyo |
| NCT04676477 | Phase 1 | Jun 11, 2021 | Daiichi Sankyo |
| NCT04619004 | Phase 2 | Dec 5, 2020 | Daiichi Sankyo |
| NCT02633800 | Phase 2 | Dec 1, 2015 | Covance, Daiichi Sankyo, Royal Marsden Hospital NHS Trust |
| NCT02350712 | Phase 1 | Dec 1, 2014 | Daiichi Sankyo |
| NCT02134015 | Phase 3 | Mar 1, 2014 | Daiichi Sankyo, Parexel |
| NCT01957280 | Phase 1 | Jun 1, 2013 | Daiichi Sankyo |
| NCT01479023 | Phase 1 | Apr 1, 2012 | Washington University in St. Louis |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 20 | 9 | 3 | 2010 |
| Merck | For profit | 6 | 6 | 2 | 2024 |
| Activa Therapeutics | For profit | 1 | 0 | 1 | 2012 |
| Covance | For profit | 1 | 0 | 1 | 2015 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Medical University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2023 |
| MedSIR | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Parexel | For profit | 1 | 0 | 1 | 2014 |
| QuantumLeap Healthcare Collaborative | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2015 |
| SOLTI Breast Cancer Research Group | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Sungkyunkwan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| U3 Pharma GmbH | For profit | 1 | 1 | 1 | 2008 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2012 |
17 organizations
Page 1 / 1